In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts
back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs
have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and
tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical
application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene
therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles
to their clinical implementation.
Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.
Rights & PermissionsPrintExport